Six Portfolio Companies of Origin Ventures Ranked in 2025 VENTURE50
Alebund
Developer of Kidney and Chronic Disease Treatment Products
UNITED IMAGING
Artificial Intelligence Medical Product Developer
XsellSmart
Stem Cell Therapy New Drug Developer
BCIFlex
Invasive High-Throughput Ultra-Thin Flexible Brain-Computer Interface System Developer
Click on the "blue words" above to follow more exciting content.
Recently, the results of the 2025 Venture50评选 organized by Zero2IPO Group and Investment界 were finally announced.VENTURE50 Investment Value Enterprise, after nineteen years of deep cultivation, has witnessed countless companies leap from "new shoots" to "unicorns," and has personally experienced China's industrial upgrading from model innovation to cutting-edge technological breakthroughs over the past 20-plus years.
Six portfolio companies of YuanSheng Ventures proudly made the list:
Alebund
UNITED IMAGING
Resproly
XsellSmart
END
About YuanSheng Ventures
Yuansheng VenturesIt is an investment institution focusing on the early and growth-stage healthcare sector, based in Suzhou BioBAY with a global reach. It has already invested in over 200 outstanding enterprises in the life sciences and healthcare field, covering areas such as new drug development, medical devices, in vitro diagnostics, precision medicine, and others.Future Medical TechnologyIn four major directions, substantial investment returns have been achieved, with 20 enterprises already listed on capital markets such as the Hong Kong Stock Exchange and the Sci-Tech Innovation Board. OrbiMed has been repeatedly ranked among the Top 10 venture capital funds in China's healthcare sector and recognized as one of the most active healthcare investment institutions in China. With a team of seasoned professional investors and a world-class scientific advisory board, OrbiMed possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry. Leveraging professionalism, dedication, and abundant industry resources, we are committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.
